Need professional-grade analysis? Visit stockanalysis.com
$29.74M
N/A
N/A
N/A
Tvardi Therapeutics, Inc. (TVRD) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $3.01, down 6.81% from the previous close.
Over the past year, TVRD has traded between a low of $2.85 and a high of $42.98. The stock has lost 85.7% over this period. It is currently 93.0% below its 52-week high.
Tvardi Therapeutics, Inc. has a market capitalization of $29.74M.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Side-by-side comparison against top Healthcare peers.